Business Context and Reporting Period
Healthcare Triangle, Inc. (HCTI), a Delaware corporation listed on The Nasdaq Stock Market LLC, filed this Form 8-K on February 26, 2026. The report details a registered direct offering of equity securities that closed on February 27, 2026.
Key Financial Metrics
- Gross Proceeds: Approximately $3.95 million.
- Securities Issued: 421,553 shares of Common Stock and 260,000 Pre-Funded Warrants.
- Offering Price: $5.81 per share for Common Stock; $5.80999 per Pre-Funded Warrant.
- Transaction Costs: A cash fee equal to 7% of aggregate gross proceeds paid to the Placement Agent (D. Boral Capital LLC), plus reimbursement of certain expenses and legal fees.
- Use of Proceeds: Working capital and general corporate purposes.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
Material Changes
The primary material change is the increase in outstanding equity and cash reserves resulting from the Offering. The Pre-Funded Warrants are immediately exercisable at a nominal price of $0.00001 per share but are subject to beneficial ownership limitations (4.99% or 9.99% caps).
Guidance, Outlook, and Risks
Management intends to use net proceeds for working capital. The filing includes significant forward-looking statements regarding the company's ability to successfully appeal a Nasdaq staff delisting determination and the potential approval of an application to trade on the OTCQB if delisted from Nasdaq. The company explicitly states that actual results may differ materially due to these uncertainties and other risk factors outlined in its March 31, 2025, Form 10-K.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 7% placement fee and other transaction expenses.
- Confirm the current status of the Nasdaq delisting determination and any pending appeals.
- Review the "Risk Factors" section of the March 31, 2025, Form 10-K for detailed operational and regulatory risks.
- Monitor the exercise of Pre-Funded Warrants and the resulting dilution impact on existing shareholders.